760 related articles for article (PubMed ID: 33270381)
1. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
[No Abstract] [Full Text] [Related]
2. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
3. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
4. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
[No Abstract] [Full Text] [Related]
5. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
[No Abstract] [Full Text] [Related]
6. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
Krammer F; Srivastava K; Alshammary H; Amoako AA; Awawda MH; Beach KF; Bermúdez-González MC; Bielak DA; Carreño JM; Chernet RL; Eaker LQ; Ferreri ED; Floda DL; Gleason CR; Hamburger JZ; Jiang K; Kleiner G; Jurczyszak D; Matthews JC; Mendez WA; Nabeel I; Mulder LCF; Raskin AJ; Russo KT; Salimbangon AT; Saksena M; Shin AS; Singh G; Sominsky LA; Stadlbauer D; Wajnberg A; Simon V
N Engl J Med; 2021 Apr; 384(14):1372-1374. PubMed ID: 33691060
[No Abstract] [Full Text] [Related]
7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
8. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Corbett KS; Nason MC; Flach B; Gagne M; O'Connell S; Johnston TS; Shah SN; Edara VV; Floyd K; Lai L; McDanal C; Francica JR; Flynn B; Wu K; Choi A; Koch M; Abiona OM; Werner AP; Moliva JI; Andrew SF; Donaldson MM; Fintzi J; Flebbe DR; Lamb E; Noe AT; Nurmukhambetova ST; Provost SJ; Cook A; Dodson A; Faudree A; Greenhouse J; Kar S; Pessaint L; Porto M; Steingrebe K; Valentin D; Zouantcha S; Bock KW; Minai M; Nagata BM; van de Wetering R; Boyoglu-Barnum S; Leung K; Shi W; Yang ES; Zhang Y; Todd JM; Wang L; Alvarado GS; Andersen H; Foulds KE; Edwards DK; Mascola JR; Moore IN; Lewis MG; Carfi A; Montefiori D; Suthar MS; McDermott A; Roederer M; Sullivan NJ; Douek DC; Graham BS; Seder RA
Science; 2021 Sep; 373(6561):eabj0299. PubMed ID: 34529476
[TBL] [Abstract][Full Text] [Related]
9. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
Hall VG; Ferreira VH; Ku T; Ierullo M; Majchrzak-Kita B; Chaparro C; Selzner N; Schiff J; McDonald M; Tomlinson G; Kulasingam V; Kumar D; Humar A
N Engl J Med; 2021 Sep; 385(13):1244-1246. PubMed ID: 34379917
[No Abstract] [Full Text] [Related]
10. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
[No Abstract] [Full Text] [Related]
11. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
12. Rapid induction of antigen-specific CD4
Painter MM; Mathew D; Goel RR; Apostolidis SA; Pattekar A; Kuthuru O; Baxter AE; Herati RS; Oldridge DA; Gouma S; Hicks P; Dysinger S; Lundgreen KA; Kuri-Cervantes L; Adamski S; Hicks A; Korte S; Giles JR; Weirick ME; McAllister CM; Dougherty J; Long S; D'Andrea K; Hamilton JT; Betts MR; Bates P; Hensley SE; Grifoni A; Weiskopf D; Sette A; Greenplate AR; Wherry EJ
Immunity; 2021 Sep; 54(9):2133-2142.e3. PubMed ID: 34453880
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
Shen X; Tang H; Pajon R; Smith G; Glenn GM; Shi W; Korber B; Montefiori DC
N Engl J Med; 2021 Jun; 384(24):2352-2354. PubMed ID: 33826819
[No Abstract] [Full Text] [Related]
14. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Falsey AR; Frenck RW; Walsh EE; Kitchin N; Absalon J; Gurtman A; Lockhart S; Bailey R; Swanson KA; Xu X; Koury K; Kalina W; Cooper D; Zou J; Xie X; Xia H; Türeci Ö; Lagkadinou E; Tompkins KR; Shi PY; Jansen KU; Şahin U; Dormitzer PR; Gruber WC
N Engl J Med; 2021 Oct; 385(17):1627-1629. PubMed ID: 34525276
[No Abstract] [Full Text] [Related]
16. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
Boyarsky BJ; Werbel WA; Avery RK; Tobian AAR; Massie AB; Segev DL; Garonzik-Wang JM
JAMA; 2021 Jun; 325(21):2204-2206. PubMed ID: 33950155
[TBL] [Abstract][Full Text] [Related]
17. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.
Corbett KS; Gagne M; Wagner DA; O' Connell S; Narpala SR; Flebbe DR; Andrew SF; Davis RL; Flynn B; Johnston TS; Stringham CD; Lai L; Valentin D; Van Ry A; Flinchbaugh Z; Werner AP; Moliva JI; Sriparna M; O'Dell S; Schmidt SD; Tucker C; Choi A; Koch M; Bock KW; Minai M; Nagata BM; Alvarado GS; Henry AR; Laboune F; Schramm CA; Zhang Y; Yang ES; Wang L; Choe M; Boyoglu-Barnum S; Wei S; Lamb E; Nurmukhambetova ST; Provost SJ; Donaldson MM; Marquez J; Todd JM; Cook A; Dodson A; Pekosz A; Boritz E; Ploquin A; Doria-Rose N; Pessaint L; Andersen H; Foulds KE; Misasi J; Wu K; Carfi A; Nason MC; Mascola J; Moore IN; Edwards DK; Lewis MG; Suthar MS; Roederer M; McDermott A; Douek DC; Sullivan NJ; Graham BS; Seder RA
Science; 2021 Dec; 374(6573):1343-1353. PubMed ID: 34672695
[TBL] [Abstract][Full Text] [Related]
18. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
Chen Y; Shen H; Huang R; Tong X; Wu C
Lancet Infect Dis; 2021 Aug; 21(8):1071-1072. PubMed ID: 34051887
[No Abstract] [Full Text] [Related]
19. Neutralizing Activity of BNT162b2-Elicited Serum.
Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
[No Abstract] [Full Text] [Related]
20. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Anderson EJ; Rouphael NG; Widge AT; Jackson LA; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Corbett KS; Swanson PA; Padilla M; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Martinez DR; Baric R; Buchanan W; Luke CJ; Phadke VK; Rostad CA; Ledgerwood JE; Graham BS; Beigel JH;
N Engl J Med; 2020 Dec; 383(25):2427-2438. PubMed ID: 32991794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
